作者: Rivera-Giraldo, Juan David ; Correa-Navarro, Yaned Milena ; Murcia-Garcia, Juan Diego ; Rodas-Rodríguez, José Mauricio ; Galviz-Quintero, Richard Alejandro

Emerging pollutants, such as parabens, pose challenges to removal through conventional wastewater treatment and require innovative approaches to remove these contaminants from water. This research evaluated the adsorption of methylparaben onto six biochars derived from fique bagasse. Batch experiments were carried out to investigate adsorption kinetics, equilibrium adsorption, and the influence of solution pH. Results showed that the adsorption capacity decreased at pH values above 6.0 for all evaluated biochars. Kinetic studies revealed that approximately 90% of methylparaben was removed within 10 h, with the pseudo-first-order (PFO) model providing the best fit to the experimental data compared to other tested models. The adsorption process was governed by both internal and external diffusion mechanisms. Equilibrium adsorption data were best described by the Langmuir isotherm, with the adsorption capacity strongly correlated to the specific surface area of the biochars. Maximum adsorption capacities (Q _max) were 134.285 mg g^-1 (FB-3Na), 87.461 mg g^-1 (FB-3C), and 64.349 mg g^-1 (FB-3). Molecular dynamics simulations provided insights into the physisorption of methylparaben onto fique bagasse biochar, confirming that the interactions were exclusively of the π-π and π-alkyl types.

2025-12-01·Toxicon: X

High-efficiency detoxification of fumonisin B1, B2 and B3 by laccase Lac-W with ABTS

作者: Xu, Kun ; Hao, Wenbo ; Geng, Chang ; Wang, Xuehui ; Yang, Wei ; Zhang, Ding ; Zhang, Jingyi ; Harmer, Nicholas J. ; Yang, Jingya

Type B fumonisins (FBs), including fumonisin B₁ (FB₁), fumonisin B₂ (FB₂) and fumonisin B₃ (FB₃), are common mycotoxins in cereal and food products. FBs contamination causes substantial social impacts and economic losses. Effective control of FBs contamination is essential for human and animal health. Laccase Lac-W has the unique property of degrading a variety of mycotoxins in the absence of mediators. Nevertheless, the degradation rates are low. In this study, a laccase mediator system (LMS), Lac-W-2, 2'-azino-bis (3-ethylbenzothiazoline-6-sulfonate) (Lac-W-ABTS), was constructed by screening different mediators, which can improve the degradation rate of FB₁ (34.70 %) within 2 h. By optimizing the reaction conditions (static conditions, pH 7.0, 40 °C, 0.5 U/mL Lac-W, 5 mM ABTS), 1 μg/mL FB₁ was effectively degraded within 24 h (88.25 %), and FB₂ (93.16 %) and FB₃ (78.24 %) were degraded efficiently. The degradation products of FB₁, FB₂ and FB₃ failed to generate cell death of intestinal porcine epithelial cells. Additionally, two detoxification products (hydrolysed FB₁ (HFB₁) and tricarboxylic acid) of FB₁ were identified by high resolution mass spectrometry. Finally, the mechanism by which ABTS acts as a more efficient electron acceptor and thus promotes Lac-W degradation of FB₁ was explained using molecular docking. This work highlights an eco-friendly bio-enzyme method that degrade FB₁, FB₂ and FB₃ simultaneously and efficiently using only one enzyme.

2025-05-01·INTERNATIONAL JOURNAL OF FOOD MICROBIOLOGY

Geographic variations in the Fusarium species and toxins associated with maize ear rot in China

Article

作者: Xu, Jianhong ; Wang, Shufang ; Lee, Yin-Won ; Shi, Jianrong ; Jiang, Can ; Chen, Daoming ; He, Can ; Qiu, Jianbo ; Lan, Jing

Diverse species of the Fusarium genus are usually the primary cause of maize ear rot, which reduces yield and quality, as well as contamination of toxic secondary metabolites. There has been little combined analysis of the diversity of pathogens and toxins in maize kernels in China, and this information is important for disease and mycotoxin control. To address this, a large-scale survey including 1217 samples was performed across China from 2019 to 2021. The most prominent contaminants were B-series fumonisins (FB₁, FB₂, and FB₃), with greater levels of FB₁ were found in southern regions. Trichothecenes and zearalenone were also serious concerns; deoxynivalenol (DON) and nivalenol (NIV) primarily originated from northeast and southwest China, respectively. Fusarium fujikuroi species complex (FFSC) and Fusarium sambucinum species complex (FSAMSC) were the most prevalent species complexes. F. verticillioides dominated in the former complex and widespread in all sampling sites. In FSAMSC, DON-producing F. graminearum and F. boothii were the predominant pathogens in the northeast, whereas all NIV type F. meridionale inhabited in the southwest. The FFSC and FSAMSC strains were pathogenic to maize ear and stalk, with varying severities. The FSAMSC strains also could infect wheat heads, and smaller amounts of toxins were found in FFSC strains inoculated wheat samples without causing any symptoms.

项与 FB-003 相关的新闻（医药）

2023-06-22

·FierceBiotech

Federation Bio cuts undisclosed number of staff months after launching first trial

A spokesperson for Federation Bio would only confirm that the company had recently undertaken a "reduction in workforce." Microbiome-focused Federation Bio has cut an undisclosed number of staff months after launching its first phase 1 trial. A spokesperson confirmed the layoffs Wednesday in a statement to Fierce Biotech but did not elaborate on how many employees were impacted or what share of the workforce was reduced. "Federation Bio can confirm that, like many biotech companies over the past several months, the company has very recently undergone a reduction in workforce," the spokesperson told Fierce. The biotech launched less than three years ago after raising $50 million in series A funds, led by Horizon Ventures and joined by Venrock and Altitude among others. The promise of tapping the microbiome as a reservoir for potential therapeutics was enticing enough for Emily Conley, who left an executive position at genomics company 23andMe to helm the ship. The biotech has not reported raising any additional funds since. Federation's lead compound, FB-001, launched into a phase 1 trial at the end of last year to treat patients with enteric hyperoxaluria, an illness that causes excess absorption of oxalate. The first part of the trial is dosing healthy volunteers with either FB-001 or placebo and the second will move into an outpatient setting, recruiting up to 16 patients with the condition to receive either the treatment or placebo. The company’s second asset, FB-003, is working through IND-enabling studies as a treatment for inflammatory bowel syndrome. Federation’s promise was enough to draw in MD Anderson to collaborate on potential microbiome treatments for patients with cancer so that they better respond to immunotherapy. The two organizations said in February that they are working on designing a “complex consortium of bacteria” sourced from a donor fecal sample that could potentially boost I-O response rates. FB-001, for example, contains 148 bacterial strains sourced from multiple donors. Microbiome companies—particularly those launched by Flagship Pioneering—have had a mixed bag of results as of late. Some have seen success, such as Flagship-founded Seres Therapeutics and Nestle Health Science, which had their oral microbiome-based therapeutic approved by the FDA in April to treat recurrent Clostridioides difficile, the first such therapy on the market. But other companies have had persistent failures, including Evelo, which cut its atopic dermatitis candidate after seeing disappointing data. Fellow Flagship company Kaleido shut down last year after stalling out.